Anavex Life Sciences
AVXL
143 hedge funds and large institutions have $164M invested in Anavex Life Sciences in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 14 closing their positions.
37% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $9.34M
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
1% less funds holding
Funds holding: 144 → 143 (-1)
0.69% less ownership
Funds ownership: 31.27% → 30.58% (-0.69%)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
20% less capital invested
Capital invested by funds: $206M → $164M (-$41.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.23M |
| 2 |
Millennium Management
New York
|
+$3.78M |
| 3 |
SG Americas Securities
New York
|
+$2.14M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.15M |
| 5 |
BlackRock
New York
|
+$973K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.24M |
| 2 |
Jane Street
New York
|
-$2.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.49M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.4M |
| 5 |
Goldman Sachs
New York
|
-$789K |
AVXL Hedge Fund Activity: Q3 2023 in Review
143 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q3 2023, worth a combined $164M — down 20% from $206M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AVXL and 13 opened new positions — a net loss of 1 holder — while 46 trimmed existing stakes and 52 added.
The largest buyer was Citadel Advisors, adding an estimated $4.23M. The largest seller was State Street, cutting an estimated $6.24M.
- 143 institutional investors held Anavex Life Sciences (AVXL) as of Q3 2023, down from 144 in Q2 2023.
- Funds reported $164M of Anavex Life Sciences stock for Q3 2023, down 20% quarter-over-quarter.
- 13 funds opened new Anavex Life Sciences positions in Q3 2023 and 14 closed out, a net change of -1 holder.
- The largest Anavex Life Sciences buyer in Q3 2023 was Citadel Advisors, an estimated $4.23M added.
- The largest Anavex Life Sciences seller in Q3 2023 was State Street, an estimated $6.24M sold.
Based on aggregated 13F filings for Q3 2023.